Can Rubicatin (Rubitidine) be used in China? Domestic approval and usage guidelines

Lurbinectedin (Lurbinectedin) is an anti-tumor drug used to treat small cell lung cancer (SCLC). It inhibits the proliferation of tumor cells by interfering with the transcription of DNA. Currently, the original drug Rubicatin has been approved for marketing in China and has become a new treatment option, especially for patients with relapsed or refractory small cell lung cancer. With the gradual acceptance of new drugs in the domestic cancer treatment field, the launch of Rubicatin provides patients with more treatment options.

Although Rubicatin has been approved in China, its specific medical insurance coverage and post-market price are not yet fully clear. Current treatment guidelines and clinical applications generally target patients with refractory or relapsed SCLC, especially those who respond poorly to chemotherapy and other targeted drugs. Rubicatin has a more significant therapeutic effect and has milder side effects than traditional chemotherapy drugs. It is usually considered a second-line or third-line treatment drug. Doctors usually consider including it in the treatment plan based on the patient's condition and individual response.

Regarding price, the domestic price of Rubicatin’s original drug has not been officially announced, but judging from the selling prices in Hong Kong and other overseas markets, its price is relatively high. In the Hong Kong market, the price of 4mg each box of the original drug may be more than 2 RMB, and the price may change due to exchange rate fluctuations. The price of the American version of Rubicon is as high as more than 90,000 yuan, while the Singapore version is relatively cheap, priced at about 3 more than 10,000 yuan. Since there is no generic version of Rubicatin yet on the market, the financial burden on patients may be greater.

In summary, rubicatin, as a new type of anticancer drug, provides a new direction for the treatment of small cell lung cancer. Although it has been approved in China, due to its high price, patients need to consider affordability when choosing. In the future, with the accumulation of treatment experience and the support of more medical insurance policies, rubicatin may become a more popular treatment drug.

Reference materials:https://www.zepzelca.com/

xa0